Why your international medical insurance premium increased

The one question the market will not answer in public

Every year, several hundred thousand internationally mobile people open a renewal invoice for medical cover and find a number materially higher than last year's, with no explanation attached beyond a benefit summary. Search for one, and the market is essentially silent. Across the five largest international medical insurers, none publishes a consumer-facing explanation of why renewal premiums rise.

There is exactly one substantive document in circulation. Bupa Global publishes a guide to its pricing philosophy that addresses the objections directly — including, in its own section headings, why a premium rises when no claim has been made, what medical inflation is, why medical advances push costs up, how exchange rates feed through, why there is no no-claims discount, and what proportion of an increase is attributable to age. Its header states that it is for broker and intermediary use only, is not intended as a consumer advertisement, and should not be relied upon by consumers in making decisions about their insurance needs.

So the fullest account of how this market prices renewals is explicitly not written for the people paying the renewals. That is the reason this page exists. What follows describes the mechanisms an insurer has itself set out, attributed and dated, so that you can read your own invoice with some idea of what is in it. It is not a substitute for asking your insurer to break down your specific increase — which is a reasonable request, and one worth making in writing.

"I have not claimed, so why has my premium gone up?"

This is the first objection Bupa addresses, and the answer is structural rather than defensive. Bupa states that it spreads claims risk across its entire customer base, so that individual customers are not penalised when they need to make a claim. Your renewal is not a re-rating of you. It is a re-rating of the pool you sit in, adjusted for the handful of things about you that are rated — principally age, country of residence and premium currency.

The same logic produces the absence of a no-claims discount, which Bupa rejects on the stated ground that it may discourage customers from seeking treatment. A product designed to remove the hesitation before seeing a doctor cannot coherently reward you for not going. The full set of factors actually rated is set out in how IPMI premiums are calculated.

The practical consequence is that "I'll shop around because I never claim" is a weaker argument than it feels. No insurer in this market will price you materially lower for a clean claims record, and the one that appears to may simply be applying a fresh medical lookback — see switching insurer without losing continuity.

Medical inflation, and how it differs from ordinary inflation

Bupa defines medical inflation as the increase in cost associated with the different types, frequency and price of medical treatments. Read that slowly, because three separate things are being combined.

Price is the ordinary-inflation component: the same procedure costs more than it did. Frequency is a volume effect: more people are treated, more often, partly because diagnosis has improved and partly because chronic disease is more prevalent. Type is the one with no consumer-price equivalent at all: the treatment being funded this year may not have existed five years ago. Bupa attributes the combined effect to advances in medical technology, the increased prevalence of chronic conditions such as diabetes and heart disease, and cancers associated with ageing populations and unhealthy lifestyles.

Bupa also makes a point that matters specifically to international policyholders and is easy to miss: the medical inflation reflected in its policies is not linked to trends in one country alone. An international plan funds treatment across a footprint, and may fund evacuation to a higher-cost market. If you live somewhere with modest general inflation and a cheap local hospital, your premium is still exposed to the cost of the systems your policy can send you to. The interaction with long-running conditions is covered in acute versus chronic conditions.

Why medical advances increase premiums

The intuitive expectation is that technology reduces cost. In healthcare funding it usually does the opposite, for two reasons that are worth separating.

The first is substitution upwards. A new therapy rarely replaces an old one at the same price; it typically replaces a cheaper, less effective treatment, or it treats a population that previously received nothing. Cancer is the clearest case — targeted therapies, immunotherapy and precision diagnostics have expanded what can be treated and what is expected to be funded. What that means for a policy is dealt with in cancer cover under IPMI.

The second is survival. Conditions that were once acute and fatal become chronic and managed, which converts a short, expensive episode into a long, recurring one. That is unambiguously good, and it is also a permanent increase in the cost of the pool. Bupa's own answer to the objection is essentially this: members expect access to the current standard of care, and the current standard of care is more expensive than last year's.

How foreign exchange rates reach your premium

Bupa prices its plans in three currencies — sterling, US dollars and euros — while paying claims in many more. Its stated approach is that it accepts claims in different currencies and always tries to absorb foreign exchange risk, but that where a currency is significantly weakened or strengthened, this can have an impact on future premiums.

The mismatch is the point. If your premium is collected in euros and a growing share of your cell's claims are settled in a currency that has appreciated against the euro, the real cost of your cover has risen without a single medical price changing. Insurers absorb small movements; sustained ones eventually appear in the rate.

There is a second exchange-rate effect on the claims side, which policyholders often mistake for underpayment. Where an invoice is issued in a currency other than the policy currency, the insurer converts it, applies any co-insurance, excess and benefit limits in the policy currency, and then converts again if you asked to be paid in something else. William Russell's 2026 personal plan agreement sets this sequence out explicitly and states that the insurer is not responsible for losses caused by rate fluctuation. Holding a policy in the currency you actually spend in removes most of that friction.

Age: what share of the increase

Bupa quantifies its age effect: on average, age increases can affect premiums by 3% to 8%. The document describes the approach as simply increasing rates as customers get older, in line with risk.

Two cautions on that figure. It is an average across a large book in a November 2024 document, so it does not predict an individual renewal. And it is only one component — it sits alongside medical inflation, portfolio rate changes and any change in your own circumstances, which is why a renewal can rise by considerably more than 8% without age being the main driver.

Insurers differ in how they apply it. Narrow annual steps produce a smooth, predictable climb. Wide age bands produce years of apparent stability followed by a step change at a boundary, which is the single most common cause of a renewal that feels inexplicable. If you are approaching a band boundary, or approaching the ages at which plan availability itself changes, read IPMI for over-70s: age limits and renewal. The related question of whether the insurer can decline to renew you at all is dealt with in annual renewability and guaranteed renewal.

"Why am I paying for maternity cover I will never use?"

Bupa treats this as a pricing question and answers it with a regulatory fact: EU regulation prevents it from pricing products on gender, though it does price on age. Once gender is unavailable as a rating factor, a maternity benefit sitting inside a bundled plan cannot be charged to the members who might use it. It is funded by the tier.

The answer is different depending on the architecture you bought. On a bundled range, maternity is a feature of the tier and cannot be removed without dropping the tier. On a core-plus-modules range, it is frequently an optional benefit that can be declined at renewal — and where it is included, it usually carries a waiting period of twelve to eighteen months, so buying it speculatively is expensive. The comparison across providers is in the existing guide to maternity cover under international health insurance.

What else is inside the number, and what to do with the invoice

Beyond inflation, age and currency, insurers name several further drivers of renewal increases: the cost of servicing the plan, changes to the plan's benefits, and changes in the cost of the specific treatments the plan covers. There is also a component that has nothing to do with the insurer at all. Policy wordings commonly provide that premiums may be affected by the introduction of, or an increase in, insurance premium tax or another local levy in the country of residence — William Russell's plan agreement says so directly, and separately requires the policyholder to pay any such tax levied by their government. That is covered in insurance premium tax on medical cover.

Three things are worth doing with a renewal invoice rather than paying it on receipt. Ask the insurer, in writing, to split the increase between age and general rate change — the figures exist internally, and a broker can usually obtain them. Check whether the plan you hold has been modified rather than merely repriced, since benefit changes take effect at renewal and are easy to miss. And decide, before the renewal date rather than after it, whether you want to change the shape of the cover, because most insurers permit changes only at renewal. The ranked options, with the cost of each stated honestly, are in reducing an IPMI renewal premium; the structural differences between the major ranges are in the existing provider comparison.